Adjuvant Therapy for Renal Cell Carcinoma

被引：5
|
作者：
Pinto, Alvaro [1 ]
机构：
[1] Univ Hosp La Paz IdiPAZ, Dept Med Oncol, Madrid 28046, Spain
来源：
CLINICAL GENITOURINARY CANCER | 2014年 / 12卷 / 06期
关键词：
Clinical trials; Immune therapy; Relapse risk; Risk reduction; Targeted therapy; POSTOPERATIVE PROGNOSTIC NOMOGRAM; RADICAL NEPHRECTOMY; PHASE-III; HIGH-RISK; STAGE-II; RANDOMIZED-TRIAL; CANCER; INTERFERON; RECURRENCE; SURVIVAL;
D O I：
10.1016/j.clgc.2014.06.012
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In the past few years, several targeted therapies have been approved by the U.S. Food and Drug Administration for the treatment of advanced renal cell carcinoma. This has led to an improvement in the progression-free survival and quality of life for these patients. Nevertheless, the use of these and other therapies in the adjuvant setting has failed to demonstrate a clear benefit. Immune therapies and hormonal or targeted therapies have been studied in this indication, and there are clinical trials currently enrolling patients with high risk of relapse. This article reviews the available data and the ongoing trials exploring the role of adjuvant therapy for kidney cancer.
引用
收藏
页码：408 / 412
页数：5
相关论文
共 50 条
  • [11] Adjuvant Therapy for Urothelial and Renal Cell Carcinoma
    Patel, Hiten D.
    Kates, Max
    Allaf, Mohamad E.
    [J]. EUROPEAN UROLOGY FOCUS, 2020, 6 (01): : 3 - 6
  • [12] Adjuvant interferon therapy for renal cell carcinoma
    Aso, Y
    Homma, Y
    Koyanagi, T
    Kumamoto, Y
    Orikasa, S
    Nakada, H
    Sato, S
    Sakata, Y
    Yamanaka, H
    Koiso, K
    Shimazaki, A
    Tazaki, H
    Machida, T
    Okada, K
    Osada, H
    Kawai, T
    Umeda, T
    Hosaka, M
    Satomi, Y
    Ogawa, A
    Kawabe, K
    Miyake, K
    Ohshima, S
    Ariyoshi, H
    Kawada, Y
    Hisazumi, H
    Tomoyoshi, T
    Yoshida, O
    Watanabe, H
    Okuyama, A
    Kishimoto, T
    Kurita, T
    Kotake, T
    Okajima, E
    Kamidono, S
    Ikoma, F
    Ohmori, H
    Usui, H
    Fujita, Y
    Kumazawa, J
    Ueda, S
    [J]. AKTUELLE UROLOGIE, 1996, 27 : 9 - 12
  • [13] Adjuvant and Neoadjuvant Therapy in Renal Cell Carcinoma
    Choueiri, Michel
    Tannir, Nizar
    Jonasch, Eric
    [J]. CURRENT CLINICAL PHARMACOLOGY, 2011, 6 (03): : 144 - 150
  • [14] Strategies for adjuvant therapy in renal cell carcinoma
    Doehn, C.
    [J]. ONKOLOGE, 2008, 14 (10): : 1065 - 1070
  • [15] Adjuvant postoperative therapy for renal cell carcinoma
    Autenrieth, M.
    Kuebler, H.
    Gschwend, J. E.
    [J]. ONKOLOGE, 2010, 16 (02): : 150 - +
  • [16] Adjuvant therapy for advanced renal cell carcinoma
    Meissner, Matthew A.
    McCormick, Barrett Z.
    Karam, Jose A.
    Wood, Christopher G.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (07) : 663 - 671
  • [17] Adjuvant and Neoadjuvant Therapy in Renal Cell Carcinoma
    Kuusk, Teele
    Bex, Axel
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (05) : 907 - 920
  • [18] Adjuvant therapy in renal cell carcinoma: Where are we?
    Eisen, Tim
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (07) : 492 - 498
  • [19] Adjuvant therapy in renal cell carcinoma: the perspective of urologists
    Spek, Annabel
    Szabados, B.
    Casuscelli, J.
    Stief, C.
    Staehler, M.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (06) : 694 - 697
  • [20] Adjuvant Therapy for Renal Cell Carcinoma: Hype or Hope?
    Cosso, Federica
    Roviello, Giandomenico
    Nesi, Gabriella
    Shabani, Sonia
    Spatafora, Pietro
    Villari, Donata
    Catalano, Martina
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (04)
12345